SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The best logo maker is essential for branding your business and standing out online. My team and I have tested the top tools for beginners and professional designers, and everyone in between.

The best free logo maker delivers a creative space for designing a logo that helps your business stand out. I've been using online design apps for over ten years, and these are my top ...

THIO combined with Libtayo shows a 38% ORR in advanced NSCLC resistant to checkpoint inhibitors, surpassing standard therapies. The phase 2 THIO-101 trial reports a disease control rate of 85% in ...

How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to ...

A rumor that food company Land O'Lakes had announced a return to its previous logo featuring a kneeling Indigenous woman on its packaging circulated online in October 2024. A Facebook post ...

The loose TV adaptation of the long-running Yakuza game series is already here after being announced in June. As a fan, I was initially both stoked and skeptical hearing the news: The games are ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The antibody is currently undergoing a phase 1/2 trial as a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo in patients with resistance to PD-1 inhibitors. That study is ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio third quarter 2024 financial results conference call ...